Carlyle to Acquire Baxter International’s Vantive Kidney Care Segment for $3.8B
Shots:
- Baxter International and Carlyle have entered into a definitive agreement as per which Carlyle will acquire Baxter's Vantive Kidney Care segment for an aggregate of $3.8B. The transaction is anticipated to conclude in H2’24 or H1’25
- As per the agreement, Baxter will get ~$3.5B in cash from the deal, estimated ~$3B after-tax proceeds, and remaining will be used for working capital and debt adjustment
- Vantive Kidney Care segment provides products and services for peritoneal dialysis, hemodialysis and organ support therapies such as continuous renal replacement therapy (CRRT)
Ref: Baxter | Image: Baxter
Related News:- Miromatrix Entered into a Collaborative Research Agreement with Baxter to Test Bioengineered Liver Replacement Therapy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
